Cargando…

SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors

SS1P is an anti-mesothelin immunotoxin composed of a targeting antibody fragment genetically fused to a truncated fragment of Pseudomonas exotoxin A. Delayed responses reported in mesothelioma patients receiving SS1P suggest that anti-tumor immunity is induced. The goal of this study is to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Leshem, Yasmin, King, Emily M., Mazor, Ronit, Reiter, Yoram, Pastan, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265743/
https://www.ncbi.nlm.nih.gov/pubmed/30441807
http://dx.doi.org/10.3390/toxins10110470
_version_ 1783375688519122944
author Leshem, Yasmin
King, Emily M.
Mazor, Ronit
Reiter, Yoram
Pastan, Ira
author_facet Leshem, Yasmin
King, Emily M.
Mazor, Ronit
Reiter, Yoram
Pastan, Ira
author_sort Leshem, Yasmin
collection PubMed
description SS1P is an anti-mesothelin immunotoxin composed of a targeting antibody fragment genetically fused to a truncated fragment of Pseudomonas exotoxin A. Delayed responses reported in mesothelioma patients receiving SS1P suggest that anti-tumor immunity is induced. The goal of this study is to evaluate if SS1P therapy renders mesothelioma tumors more sensitive to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint blockade. We evaluated the ability of SS1P to induce adenosine triphosphate (ATP) secretion and calreticulin expression on the surface of AE17M mouse mesothelioma cells. Both properties are associated with immunogenic cell death. Furthermore, we treated these tumors with intra-tumoral SS1P and systemic CTLA-4. We found that SS1P increased the release of ATP from AE17M cells in a dose and time-dependent manner. In addition, SS1P induced calreticulin expression on the surface of AE17M cells. These results suggest that SS1P promotes immunogenic cell death and could sensitize tumors to anti-CTLA-4 based therapy. In mouse studies, we found that the combination of anti-CTLA-4 with intra-tumoral SS1P induced complete regressions in most mice and provided a statistically significant survival benefit compared to monotherapy. The surviving mice were protected from tumor re-challenge, indicating the development of anti-tumor immunity. These findings support the use of intra-tumoral SS1P in combination with anti-CTLA-4.
format Online
Article
Text
id pubmed-6265743
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62657432018-12-07 SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors Leshem, Yasmin King, Emily M. Mazor, Ronit Reiter, Yoram Pastan, Ira Toxins (Basel) Article SS1P is an anti-mesothelin immunotoxin composed of a targeting antibody fragment genetically fused to a truncated fragment of Pseudomonas exotoxin A. Delayed responses reported in mesothelioma patients receiving SS1P suggest that anti-tumor immunity is induced. The goal of this study is to evaluate if SS1P therapy renders mesothelioma tumors more sensitive to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint blockade. We evaluated the ability of SS1P to induce adenosine triphosphate (ATP) secretion and calreticulin expression on the surface of AE17M mouse mesothelioma cells. Both properties are associated with immunogenic cell death. Furthermore, we treated these tumors with intra-tumoral SS1P and systemic CTLA-4. We found that SS1P increased the release of ATP from AE17M cells in a dose and time-dependent manner. In addition, SS1P induced calreticulin expression on the surface of AE17M cells. These results suggest that SS1P promotes immunogenic cell death and could sensitize tumors to anti-CTLA-4 based therapy. In mouse studies, we found that the combination of anti-CTLA-4 with intra-tumoral SS1P induced complete regressions in most mice and provided a statistically significant survival benefit compared to monotherapy. The surviving mice were protected from tumor re-challenge, indicating the development of anti-tumor immunity. These findings support the use of intra-tumoral SS1P in combination with anti-CTLA-4. MDPI 2018-11-14 /pmc/articles/PMC6265743/ /pubmed/30441807 http://dx.doi.org/10.3390/toxins10110470 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Leshem, Yasmin
King, Emily M.
Mazor, Ronit
Reiter, Yoram
Pastan, Ira
SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
title SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
title_full SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
title_fullStr SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
title_full_unstemmed SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
title_short SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
title_sort ss1p immunotoxin induces markers of immunogenic cell death and enhances the effect of the ctla-4 blockade in ae17m mouse mesothelioma tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265743/
https://www.ncbi.nlm.nih.gov/pubmed/30441807
http://dx.doi.org/10.3390/toxins10110470
work_keys_str_mv AT leshemyasmin ss1pimmunotoxininducesmarkersofimmunogeniccelldeathandenhancestheeffectofthectla4blockadeinae17mmousemesotheliomatumors
AT kingemilym ss1pimmunotoxininducesmarkersofimmunogeniccelldeathandenhancestheeffectofthectla4blockadeinae17mmousemesotheliomatumors
AT mazorronit ss1pimmunotoxininducesmarkersofimmunogeniccelldeathandenhancestheeffectofthectla4blockadeinae17mmousemesotheliomatumors
AT reiteryoram ss1pimmunotoxininducesmarkersofimmunogeniccelldeathandenhancestheeffectofthectla4blockadeinae17mmousemesotheliomatumors
AT pastanira ss1pimmunotoxininducesmarkersofimmunogeniccelldeathandenhancestheeffectofthectla4blockadeinae17mmousemesotheliomatumors